Victory Capital Management
GBIO

Victory Capital Management’s Generation Bio GBIO Stock Holding History

Victory Capital Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,921
Closed -$102K – 2639
2022
Q3 		$102K Buy
1,921
+149
+8% +$9.32K ﹤0.01% 2476
2022
Q2 		$116K Sell
1,772
-2
-0.1% -$131 ﹤0.01% 2443
2022
Q1 		$112K Sell
1,774
-7,883
-82% -$457K ﹤0.01% 2499
2021
Q4 		$683K Sell
9,657
-117,698
-92% -$20.5M ﹤0.01% 2000
2021
Q3 		$31.9M Buy
127,355
+15,257
+14% +$3.65M 0.03% 708
2021
Q2 		$30.2M Buy
112,098
+3,817
+4% +$1.14M 0.03% 752
2021
Q1 		$30.8M Buy
108,281
+36,346
+51% +$11.6M 0.03% 744
2020
Q4 		$20.4M Sell
71,935
-14,765
-17% -$4.74M 0.02% 863
2020
Q3 		$26.8M Buy
86,700
+1,831
+2% +$438K 0.03% 670
2020
Q2 		$17.8M Buy
+84,869
New +$18.9M 0.02% 824

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return